Callan Family Office LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

by · The Cerbat Gem

Callan Family Office LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 203.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,715 shares of the pharmaceutical company’s stock after acquiring an additional 11,198 shares during the period. Callan Family Office LLC’s holdings in Vertex Pharmaceuticals were worth $7,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. TFR Capital LLC. boosted its stake in shares of Vertex Pharmaceuticals by 4.1% in the second quarter. TFR Capital LLC. now owns 4,950 shares of the pharmaceutical company’s stock worth $2,204,000 after acquiring an additional 194 shares during the last quarter. Boomfish Wealth Group LLC boosted its stake in shares of Vertex Pharmaceuticals by 3.8% in the second quarter. Boomfish Wealth Group LLC now owns 5,243 shares of the pharmaceutical company’s stock worth $2,334,000 after acquiring an additional 192 shares during the last quarter. US Bancorp DE boosted its stake in shares of Vertex Pharmaceuticals by 4.1% in the second quarter. US Bancorp DE now owns 33,583 shares of the pharmaceutical company’s stock worth $14,951,000 after acquiring an additional 1,324 shares during the last quarter. Baxter Bros Inc. boosted its stake in shares of Vertex Pharmaceuticals by 17.3% in the second quarter. Baxter Bros Inc. now owns 1,441 shares of the pharmaceutical company’s stock worth $642,000 after acquiring an additional 213 shares during the last quarter. Finally, Notis McConarty Edward boosted its stake in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Notis McConarty Edward now owns 7,381 shares of the pharmaceutical company’s stock worth $3,286,000 after acquiring an additional 106 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 1.5%

Shares of Vertex Pharmaceuticals stock opened at $414.86 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The business’s fifty day simple moving average is $394.99 and its 200-day simple moving average is $440.30. The firm has a market cap of $106.37 billion, a PE ratio of 29.65 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the company posted ($12.83) EPS. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VRTX. Royal Bank Of Canada lowered their price target on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday. Cantor Fitzgerald lowered their price objective on Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Finally, Guggenheim lowered their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.43.

Check Out Our Latest Analysis on VRTX

Insider Activity

In other news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).